All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Undisclosed Upfront Cash: $11.0 million
Deal Type: Collaboration February 01, 2021
Details:
Exelixis will utilize Adagene’s proprietary SAFEbody™ technology to develop novel masked antibody-drug conjugates (ADCs) with potential for improved therapeutic index.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATG-022
Therapeutic Area: Oncology Product Name: ATG-022
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Antengene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 01, 2021
Details:
WuXi Biologics and WuXi STA will provide services for the process development, scale-up, and GMP manufacturing of ADC drug intermediates. Antengene will focus on the discovery of the monoclonal antibody, the core element of ADCs which includes ATG-022.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Arcus Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 09, 2020
Details:
Under the terms of the Strategic collaboration, parties will discover anti-CD39 antibodies using WuXi Bio’s proprietary technology. This CD39 collaboration represents the fourth antibody development program on which the two companies have joined forces.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TUB-010
Therapeutic Area: Oncology Product Name: TUB-010
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Tubulis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 02, 2020
Details:
WuXi Biologics and WuXi STA will perform scale-up, process development and GMP manufacturing for the ADC product intermediates. The first program from Tubulis’ pipeline the companies will collaborate on is TUB-010.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HG030
Therapeutic Area: Oncology Product Name: HG030
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Guangzhou Baiyunshan Pharmaceutical Holdings
Deal Size: Undisclosed Upfront Cash: $5.8 million
Deal Type: Licensing Agreement November 10, 2020
Details:
Baiyunshan will get exclusive rights to develop and market HG030 in mainland China, and will pay HitGen an upfront licensing fee and a series of milestones and royalty of sales as the product progresses through clinical trials and launches in the mainland China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: CMB International
Deal Size: $142.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing September 24, 2020
Details:
Project Integrum aims at developing, and bringing to market novel therapeutic antibody candidates for difficult druggable targets. Biocytogen's Pipeline includes, RenMab-based target knockout mice, customized target humanized mouse models and gene therapy platforms.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 7×21 CAR-T cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
Details:
Study results indicated the 7×21 CAR-T cells significantly outperformed the conventional CAR-T cells in cell proliferation and chemotaxis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TJ-CD4B
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
The pre-clinical validation of TJ-CD4B/ABL111 to be presented at AACR signifies the overall progress of I-Mab’s bispecific antibody portfolio, reflecting Company’s discovery and CMC capabilities to engineer novel molecules with combined target specificities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APG-3526
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
Ascentage Pharma will report six research results involving multiple cancer types in poster presentations during the meeting. Among them, APG-3526, the company's newest drug candidate, will be presented for the first time.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anti-SIRP-alpha antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Alector
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 26, 2020
Details:
Under the agreement, Innovent will lead the development and commercialization of the molecule in China, including the manufacturing of the product.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
